Analysts Set Veeva Systems Inc. (NYSE:VEEV) PT at $278.70

Shares of Veeva Systems Inc. (NYSE:VEEV) have been assigned a consensus rating of “Moderate Buy” from the twenty-six brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation, sixteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $278.6957.

A number of equities research analysts have recently commented on VEEV shares. Canaccord Genuity Group lowered their price target on shares of Veeva Systems from $280.00 to $235.00 and set a “hold” rating for the company in a report on Thursday, March 5th. Stifel Nicolaus boosted their target price on shares of Veeva Systems from $212.00 to $245.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Weiss Ratings downgraded shares of Veeva Systems from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 12th. JPMorgan Chase & Co. lowered their target price on shares of Veeva Systems from $330.00 to $296.00 and set an “overweight” rating for the company in a report on Friday, February 20th. Finally, Piper Sandler lowered their target price on shares of Veeva Systems from $355.00 to $285.00 and set an “overweight” rating for the company in a report on Thursday, March 5th.

Veeva Systems Price Performance

Shares of NYSE VEEV opened at $171.44 on Friday. The company has a market cap of $28.00 billion, a PE ratio of 31.69, a price-to-earnings-growth ratio of 0.76 and a beta of 0.92. Veeva Systems has a 12 month low of $148.05 and a 12 month high of $310.50. The company has a 50-day simple moving average of $174.52 and a 200-day simple moving average of $215.44.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Wednesday, March 4th. The technology company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.12. The business had revenue of $835.95 million during the quarter, compared to the consensus estimate of $810.95 million. Veeva Systems had a net margin of 28.44% and a return on equity of 13.80%. The company’s quarterly revenue was up 16.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.74 earnings per share. Veeva Systems has set its FY 2027 guidance at 8.850- EPS and its Q1 2027 guidance at 2.130-2.14 EPS. On average, analysts anticipate that Veeva Systems will post 6.41 EPS for the current year.

Veeva Systems News Summary

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: S&P 500 inclusion + management change — Veeva’s announced addition to the S&P 500 (effective May 7) and a reported general counsel transition sparked index-driven buying and a volume gap-up as ETFs and passive funds adjust holdings. Veeva Systems (VEEV) Is Up 6.9% After S&P 500 Addition and GC Transition News
• Positive Sentiment: GenAI / industry positioning — multiple industry write-ups flag Veeva as a beneficiary of rising GenAI adoption in healthcare workflows, supporting the growth narrative for its Vault platform and CRM suites. This thematic coverage attracts software-focused investors. Zacks Industry Outlook Highlights Veeva Systems, Doximity and Omnicell
• Positive Sentiment: Solid fundamentals and capital return — recent quarterly results showed an earnings beat and double-digit revenue growth; plus a $2.0B buyback program remains in place, which can support shares over time as buybacks reduce float. Veeva Systems Stock Page
• Neutral Sentiment: Brokerage coverage / analyst consensus — media pieces highlighting average broker recommendations and “Moderate Buy” consensus can amplify momentum but are not new fundamentals; analyst price targets remain wide. Brokers Suggest Investing in Veeva (VEEV): Read This Before Placing a Bet
• Neutral Sentiment: Repeat thematic coverage — additional Zacks / industry write-ups reiterate the GenAI tailwind; useful for sentiment but largely confirmatory rather than new catalysts. 3 Medical Info Systems Stocks Riding the GenAI Wave
• Negative Sentiment: Insider selling disclosed — Director Priscilla Hung sold 750 shares under a pre-arranged Rule 10b5‑1 plan. While routine, the sale can trigger short-term concern among some investors about insider conviction. Insider Selling: Veeva Systems Director Priscilla Hung Sells 750 Shares

Insider Transactions at Veeva Systems

In related news, Director Priscilla Hung sold 750 shares of the business’s stock in a transaction that occurred on Thursday, April 30th. The shares were sold at an average price of $155.64, for a total value of $116,730.00. Following the completion of the sale, the director directly owned 3,253 shares in the company, valued at approximately $506,296.92. The trade was a 18.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 10.30% of the company’s stock.

Institutional Investors Weigh In On Veeva Systems

Institutional investors have recently bought and sold shares of the stock. GPS Wealth Strategies Group LLC grew its holdings in Veeva Systems by 196.4% in the third quarter. GPS Wealth Strategies Group LLC now owns 83 shares of the technology company’s stock valued at $25,000 after purchasing an additional 55 shares during the period. SHP Wealth Management purchased a new stake in Veeva Systems in the fourth quarter valued at approximately $26,000. Board of the Pension Protection Fund purchased a new stake in Veeva Systems in the fourth quarter valued at approximately $27,000. Raiffeisen Bank International AG acquired a new position in Veeva Systems during the third quarter valued at approximately $28,000. Finally, Newbridge Financial Services Group Inc. lifted its position in Veeva Systems by 322.6% during the fourth quarter. Newbridge Financial Services Group Inc. now owns 131 shares of the technology company’s stock valued at $29,000 after buying an additional 100 shares in the last quarter. 88.20% of the stock is currently owned by hedge funds and other institutional investors.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.